1600-6143/asset/olbannerleft.gif?v=1&s=c46a3f174bfd9c6eb548cc809401524372c32e90)
1600-6143/asset/olbannerright.gif?v=1&s=9fc9790fa8ad5ef85aeaf408bf0d3d969d2fc012)
Immunobiology of Chronic Lung Allograft Dysfunction: New Insights from the Bench and Beyond
Article first published online: 10 JUN 2009
DOI: 10.1111/j.1600-6143.2009.02690.x
© 2009 The Authors Journal compilation © 2009 The American Society of Transplantation and the American Society of Transplant Surgeons
Additional Information
How to Cite
Shilling, R. A. and Wilkes, D. S. (2009), Immunobiology of Chronic Lung Allograft Dysfunction: New Insights from the Bench and Beyond. American Journal of Transplantation, 9: 1714–1718. doi: 10.1111/j.1600-6143.2009.02690.x
Publication History
- Issue published online: 16 JUL 2009
- Article first published online: 10 JUN 2009
- Received 17 February 2009, revised 22 March 2009 and accepted for publication 07 April 2009
- Abstract
- Article
- References
- Cited By
Keywords:
- Alloimmunity;
- autoimmunity;
- bronchiolitis obliterans syndrome;
- IL-17;
- lung transplantation;
- obliterative bronchiolitis
Key issues in lung transplant immunology as they relate to the development of chronic allograft dysfunction including obliterative bronchiolitis involve early graft dysfunction, autoimmunity, and regulatory T cells.
The first successful human lung transplants were performed in the 1980s. Since that time lung transplantation has been a therapeutic modality for end-stage pulmonary diseases. However, chronic rejection, known as obliterative bronchiolitis (OB)/bronchiolitis obliterans syndrome (BOS), is the key reason why the 5-year survival is only 50%, which is significantly worse than most other solid organ transplants. Recent studies have provided exciting advances that are beginning to be translated into findings in humans. This review will highlight the current advances in understanding the mechanisms of OB/BOS in lung transplant recipients.